Understanding the genetic causes of hidradenitis suppurativa in African Americans
Official title: Establishing the contributions of monogenic etiologies to hidradenitis suppurativa pathogenesis
Funded at New York University School of Medicine · NIH-11159205 · Data updated 2026-11-12
This study is looking at the genes that might cause hidradenitis suppurativa, a painful skin condition, especially in African Americans who are affected more than others, to help find better treatments and care for everyone dealing with this issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $700,744 |
| NIH project number | 7R01AR080796-02 |
| Project ID | NIH-11159205 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American individuals diagnosed with hidradenitis suppurativa.
✕Less likely to help
Patients who do not have hidradenitis suppurativa or those outside the African American demographic may not benefit from this research.
What this research studies
This research investigates the genetic factors contributing to hidradenitis suppurativa (HS), a painful inflammatory skin condition, particularly focusing on the African American population who are disproportionately affected. The study aims to identify specific genetic mutations that may lead to HS, using advanced genetic analysis techniques. By including a larger cohort of African American patients, the research seeks to fill gaps in previous studies that have largely excluded this group. The findings could help in developing targeted treatments and improving management strategies for HS.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hidradenitis suppurativa, particularly for African American patients who currently face significant challenges in managing the condition.
How similar studies have gone: While there have been few genetic studies on hidradenitis suppurativa, the approach of focusing on monogenic causes in underrepresented populations is relatively novel and has shown promise in other inflammatory conditions.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Petukhova, Lynn — New York University School of Medicine
- Study coordinator: Petukhova, Lynn
Related research
Other NIH-funded projects on the same topics.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Botulinum toxin blocks nerve signals to immune cells to treat hidradenitis suppurativa
This NIH grant tests a new approach to hidradenitis suppurativa by using botulinum toxin to interrupt nerve signals that may drive skin inflammation in patients.
-
Precision therapies for hidradenitis suppurativa using AI
A doctor-researcher team at UC San Francisco is using advanced computer methods to find personalized drug options to treat hidradenitis suppurativa.
-
Injectable Hydrogel for HS: a localized therapy to ease painful skin disease
A new baricitinib hydrogel is being developed to deliver pain relief and reduce inflammation directly in hidradenitis suppurativa (HS) lesions, potentially lowering systemic side effects.
-
Whole-genome sequencing to understand hidradenitis suppurativa in diverse groups
Researchers will study the genetic factors that contribute to hidradenitis suppurativa, especially in African American, Hispanic/Latino, and White patients, to better understand why some people are more affected.
-
Understanding the Genes Behind Hidradenitis Suppurativa in teens and young adults
A study to find genetic factors that contribute to hidradenitis suppurativa (HS), a painful skin condition that often starts in adolescence and affects many Black individuals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.